Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy

MT Newswires Live03-05

Erasca (ERAS) said Thursday that it has entered into a clinical trial collaboration and supply agreement with Tango Therapeutics (TNGX) to evaluate its experimental drug, ERAS-0015, in combination with Tango's vopimetostat.

The company said the agreement would support phase 1/2 trial, which will target patients with a type of pancreatic cancer or non-small cell lung cancer.

Erasca said that, as part of the agreement, it will supply ERAS-0015 free of charge, while Tango will serve as the trial sponsor.

Both companies will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive, Erasca said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617542120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617542120","market":"fut","top_or_hot":-1,"title":"Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy","media":"MT Newswires Live","content":"<html><body><p> Erasca (ERAS) said Thursday that it has entered into a clinical trial collaboration and supply agreement with Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TNGX) to evaluate its experimental drug, ERAS-0015, in combination with Tango's vopimetostat.</p><p>The company said the agreement would support phase 1/2 trial, which will target patients with a type of pancreatic cancer or non-small cell lung cancer.</p><p>Erasca said that, as part of the agreement, it will supply ERAS-0015 free of charge, while Tango will serve as the trial sponsor.</p><p>Both companies will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive, Erasca said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-05 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Erasca (ERAS) said Thursday that it has entered into a clinical trial collaboration and supply agreement with Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TNGX) to evaluate its experimental drug, ERAS-0015, in combination with Tango's vopimetostat.</p><p>The company said the agreement would support phase 1/2 trial, which will target patients with a type of pancreatic cancer or non-small cell lung cancer.</p><p>Erasca said that, as part of the agreement, it will supply ERAS-0015 free of charge, while Tango will serve as the trial sponsor.</p><p>Both companies will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive, Erasca said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2617542120","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617542120","pubTimestamp":1772714585,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Erasca  said Thursday that it has entered into a clinical trial collaboration and supply agreement with Tango Therapeutics  to evaluate its experimental drug, ERAS-0015, in combination with Tango's vopimetostat.The company said the agreement would support phase 1/2 trial, which will target patients with a type of pancreatic cancer or non-small cell lung cancer.Erasca said that, as part of the agreement, it will supply ERAS-0015 free of charge, while Tango will serve as the trial sponsor.Both companies will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive, Erasca said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ERAS":"Erasca, INC.","BK4583":"猴痘概念","TNGX":"Tango Therapeutics Inc.","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","TNXP":"Tonix Pharmaceuticals Holding Co"},"translate_title":"Erasca与Tango Therapeutics合作开展癌症联合治疗1/2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":1,"ERAS":1.5,"TNXP":0.9,"LENZ":1.5},"content_text":"Erasca (ERAS) said Thursday that it has entered into a clinical trial collaboration and supply agreement with Tango Therapeutics (TNGX) to evaluate its experimental drug, ERAS-0015, in combination with Tango's vopimetostat.The company said the agreement would support phase 1/2 trial, which will target patients with a type of pancreatic cancer or non-small cell lung cancer.Erasca said that, as part of the agreement, it will supply ERAS-0015 free of charge, while Tango will serve as the trial sponsor.Both companies will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive, Erasca said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617542120","isCrawlerRequest":true}